Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
A standard diet program often follows a general formula intended for a wide audience
Data Items Collected The following variables were charted for each included source of evidence: Bibliographic information: author, year, country, funding Study characteristics: design, phase, sample size, duration, setting Population: diabetes type, overweight/obesity definitions, CKD stage, albuminuria status, baseline eGFR, concomitant therapies Intervention(s) or exposure: GLP-1 receptor agonist or tirzepatide (dose, route, duration) Comparator(s): placebo or active comparator Outcomes: kidney and cardiorenal measures (eGFR slope, composite renal endpoints, albuminuria, safety) Main findings: direction and magnitude of renal effect Appraisal and evidence rating: methodological quality, certainty, and relevance Notes: contextual remarks, analytic subgroups, and comments on applicability Appraisal and Evidence Rating Because this review was conducted to inform the RAND/UCLA Appropriateness Method for SLANH, each included study underwent a structured critical appraisal using the appropriate validated tool for its design: Randomized controlled trials: Cochrane Risk of Bias 2 (RoB 2) [10] Post hoc or secondary RCT analyses: adapted Cochrane or NIH tool Observational comparative studies: ROBINS-I [11] The AI tool was programmed to assist in pre-classifying bias domains (e.g., randomization, blinding, confounding) and to highlight textual evidence for reviewer judgment
- ( The glucagon-like peptide-1 analogue exendin-4 decreases the rewarding value of food and drug rewards - (
Further clinical research is needed to better understand its long-term efficacy and safety in this context
Zhu, H., Jia, Z., Misra, H
AOD-9604 is not an approved medicine
